Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SMRX 11

Next Previous
Drug Profile

SMRX 11

Alternative Names: Clot-buster protein; Clot-specific streptokinase; CSSK; SMRX11

Latest Information Update: 01 Aug 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Institute of Microbial Technology
  • Developer Nostrum Pharmaceuticals; Symmetrix Biotech
  • Class Coenzymes; Plasminogen activator enzymes; Recombinant fusion proteins; Recombinant proteins; Thrombolytics
  • Mechanism of Action Fibrinolytic agents; Plasmin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Myocardial infarction
  • No development reported Thrombosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Thrombosis(In volunteers) in India (IV)
  • 24 Mar 2014 SMRX 11 is still in preclinical trials for thrombosis (IV) in India
  • 10 Mar 2014 Symmetrix Pharmaceuticals plans a phase II trial for Myocardial infarction in India (CTRI/2014/03/004442)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top